Dark

Check out our API

APTO
Aptose Biosciences, Inc.
stock NASDAQ

Inactive

Apr 1, 2025

1.71USD-45.714%(-1.44)670,384

Pre-market

Dec 31, 1969 7:00:00 PM EST

0.00USD-100.000%(-3.15)0

After-hours

Dec 31, 1969 7:00:00 PM EST

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Dec 29, 2021

07:30AM EST Aptose to Participate in Two Biotech Events in January 2022 GlobeNewswire Inc

Dec 21, 2021

05:28AM EST HC Wainwright & Co. Maintains Buy on Aptose Biosciences, Lowers Price Target to $12 Benzinga

Dec 20, 2021

07:38AM EST Aptose Biosciences Announces Its Decision To Discontinue Further Clinical Development Of APTO-253 Benzinga

07:30AM EST -- Clinical development of the MYC repressor APTO-253 will be discontinued -- GlobeNewswire Inc

Dec 14, 2021

08:22AM EST The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks Benzinga

Dec 13, 2021

04:32PM EST Aptose Biosciences Reports The Oral Myeloid Kinome Inhibitor HM43239 Has Demonstrated Durable Single Agent Activity In Patients With Relapsed Or Refractory Acute Myeloid Leukemia Benzinga

04:30PM EST HM43239 Data Featured in Oral Presentation at theAmerican Society of HematologyAnnual Meeting GlobeNewswire Inc

Dec 11, 2021

05:50PM EST Aptose Biosciences Published Poster - A Phase 1a/b Dose Escalation Study of Luxeptinib in R/R AML for ASH 2021 Benzinga

Nov 29, 2021

07:30AM EST HM43239 clinical update in AML after oral presentation at 2021 ASH Annual MeetingLuxeptinib clinical update in AML and B-cell cancers GlobeNewswire Inc

Nov 22, 2021

04:02PM EST Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will be participating in the Piper Sandler 33rd Annual Healthcare Conference, being held virtually. GlobeNewswire Inc

Nov 12, 2021

06:11AM EST HC Wainwright & Co. Maintains Buy on Aptose Biosciences, Raises Price Target to $14 Benzinga

Nov 11, 2021

04:04PM EST Aptose Biosciences Q3 EPS $(0.13) Beats $(0.17) Estimate Benzinga

04:01PM EST - Conference call and webcast at 5:00 pm ET today - GlobeNewswire Inc

08:03AM EST The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts Benzinga

03:55AM EST Earnings Scheduled For November 11, 2021 Benzinga

Nov 4, 2021

06:46AM EDT Aptose Enters Into Exclusive Worldwide License Agreement With Hanmi Pharmaceutical For Clinical-Stage Myeloid Kinome Inhibitor HM43239; Hanmi Will Receive An Upfront Payment Of $12.5M, Including $5M In Cash And $7.5M In Aptose Shares Along With Up To $407.5 Million In Future Milestone Payments Benzinga

06:46AM EDT Aptose Enters Into Exclusive Worldwide License Agreement With Hanmi Pharmaceutical For Clinical-Stage Myeloid Kinome Inhibitor HM43239; Hanmi Will Receive An Upfront Payment Of $12.5M, Including $5M In Cash And $7.5M In Aptose Shares Benzinga

06:00AM EDT HM43239 delivers multiple complete responses (CRs) in diverse R/R AML patients GlobeNewswire Inc

Oct 26, 2021

07:30AM EDT Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will report financial results for the quarter ended September 30, 2021, and provide a corporate update on Thursday, November 11, 2021, after the close of the market. GlobeNewswire Inc

Oct 25, 2021

08:00AM EDT Janet Clennett, CPA, appointed Vice President, Finance GlobeNewswire Inc

Oct 1, 2021

07:56AM EDT The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO Benzinga

Sep 30, 2021

07:43AM EDT The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug Benzinga

Aug 31, 2021

09:40AM EDT Aptos Biosciences Granted U.S. Patent Titled 'Compositions and methods for treating cancers' Benzinga

Aug 30, 2021

07:30AM EDT Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will participate at the upcoming conferences in September 2021: GlobeNewswire Inc

Aug 20, 2021

07:45AM EDT The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data Benzinga

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Aug 12, 2021

08:09AM EDT The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma Benzinga

Aug 3, 2021

04:30PM EDT Aptose Biosciences Q2 EPS $(0.15) Misses $(0.14) Estimate Benzinga

04:01PM EDT - Conference call and webcast at 5:00 pm EDT today - GlobeNewswire Inc

07:55AM EDT The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business Benzinga

03:52AM EDT Earnings Scheduled For August 3, 2021 Benzinga

Aug 1, 2021

11:19AM EDT The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs Benzinga

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 27, 2021

11:13AM EDT The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts Benzinga

Jul 20, 2021

04:01PM EDT Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will report financial results for the quarter ended June 30, 2021, and provide a corporate update on Tuesday, August 3, 2021, after the close of the market. GlobeNewswire Inc

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

Jul 16, 2021

07:37AM EDT The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study Benzinga

Jul 15, 2021

08:08AM EDT The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs Benzinga

Jul 14, 2021

07:48AM EDT The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues Benzinga

Jul 13, 2021

08:05AM EDT The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data Benzinga

Jul 9, 2021

07:36AM EDT The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO Benzinga

Jun 23, 2021

07:35AM EDT The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway Benzinga

Jun 22, 2021

08:12AM EDT The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal Benzinga

Jun 17, 2021

08:33AM EDT The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme Benzinga

Jun 11, 2021

03:04PM EDT Mid-Afternoon Market Update: Crude Oil Rises 1%; Janux Therapeutics Shares Jump Benzinga

02:17PM EDT Aptose Biosciences Stock Tumbles As Luxeptinib Fails To Impress At EHA2021 Virtual Congress Benzinga

07:56AM EDT Aptose Presents For Corporate Update Event Benzinga

07:55AM EDT Aptose Presents Highlights from EHA During Corporate Update Event GlobeNewswire Inc

Jun 1, 2021

04:30PM EDT Aptose Biosciences Announces Results of Annual Meeting of Shareholders GlobeNewswire Inc

May 27, 2021

07:30AM EDT Clinical Updates for Luxeptinib in AML & B-cell Cancers and for APTO-253 in AML & MDS GlobeNewswire Inc

May 12, 2021

07:30AM EDT Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will participate in upcoming investor conferences: GlobeNewswire Inc

May 4, 2021

04:14PM EDT Aptose Biosciences Q1 EPS $(0.18) Misses $(0.14) Estimate Benzinga

04:01PM EDT - Conference call and webcast at 4:30 pm EDT today - GlobeNewswire Inc

08:10AM EDT The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data Benzinga

Apr 26, 2021

04:02PM EDT Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will report financial results for the quarter ended March 31, 2021, and provide a corporate update on Tuesday, May 4, 2021, after the close of the market. GlobeNewswire Inc

Apr 8, 2021

07:30AM EDT Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in Canaccord Genuitys 2021 Horizons in Oncology Virtual Conference: GlobeNewswire Inc

Mar 25, 2021

09:50AM EDT What's Happening With APTO Stock And SNES Stock Today? Benzinga

Mar 24, 2021

02:32PM EDT Mid-Afternoon Market Update: Dow Surges 270 Points; GameStop Shares Drop After Q4 Earnings Benzinga

12:29PM EDT Mid-Day Market Update: Crude Oil Rises 3.5%; Second Sight Medical Products Shares Plunge Benzinga

10:25AM EDT What's Happening With APTO Stock And SNES Stock Today? Benzinga

10:17AM EDT Mid-Morning Market Update: Markets Mostly Higher; General Mills Reports Downbeat Q3 Earnings Benzinga

06:59AM EDT Oppenheimer Maintains Outperform on Aptose Biosciences, Raises Price Target to $9 Benzinga

Mar 23, 2021

04:03PM EDT Aptose Biosciences Q4 EPS $(0.17) Misses $(0.14) Estimate Benzinga

04:01PM EDT Aptose Reports Results for the Fourth Quarter and Full Year 2020 GlobeNewswire Inc

04:26AM EDT Earnings Scheduled For March 23, 2021 Benzinga

Mar 16, 2021

07:30AM EDT George Melko, Pharm.D. joins as Vice President, Regulatory Affairs GlobeNewswire Inc

Mar 2, 2021

04:02PM EST Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the year and quarter ended December 31, 2020, on Tuesday, March 23, 2021 after the close of the market. GlobeNewswire Inc

Feb 26, 2021

08:17AM EST The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida Benzinga

Jan 6, 2021

05:25PM EST Aptose Biosciences Says Selling Shareholders Offering Of 4.74M Shares Benzinga

Dec 16, 2020

07:15AM EST The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal Benzinga

Dec 8, 2020

03:37PM EST Why Aptose Biosciences Stock Is Trading Lower Today Benzinga

Dec 7, 2020

10:10AM EST Mid-Morning Market Update: Markets Open Mostly Lower; Seacor Holdings To Go Private Benzinga

Dec 6, 2020

05:30PM EST Aptose Presents Highlights from ASH and Corporate Update Event GlobeNewswire Inc

08:41AM EST Week Ahead In Biotech: FDA To Decide On Emergency Use Of Pfizer's COVID Vaccine, Hematology Conference Presentations Pick Up Pace Benzinga

Dec 1, 2020

07:30AM EST Corporate event to provide clinical update for CG-806 in AML and B-cell Cancers GlobeNewswire Inc

Nov 29, 2020

08:59AM EST The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions Benzinga

Nov 10, 2020

04:05PM EST Aptose Biosciences Q3 EPS $(0.15), Inline Benzinga

04:01PM EST Dosing Initiated in CG-806 Phase 1 a/b Study in AML Patients at 450mg Dose Level GlobeNewswire Inc

Nov 4, 2020

10:18AM EST Aptose To Present CG-806 And APTO-253 Data At The 2020 American Society Of Hematology Annual Meeting Benzinga

10:17AM EST Aptose to Present CG-806 and APTO-253 Data at the 2020 ASH Annual GlobeNewswire Inc

Oct 27, 2020

04:01PM EDT Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the quarter ended September 30, 2020 on Tuesday, November 10, 2020, after the close of the market. GlobeNewswire Inc

Oct 19, 2020

09:07AM EDT Cantor Fitzgerald Initiates Coverage On Aptose Biosciences with Overweight Rating, Announces Price Target of C$10 Benzinga

07:13AM EDT Aptose Biosciences Begins Dosing Of CG-806 In Patients With Acute Myeloid Leukemia RTTNews

07:10AM EDT Aptose Initiates Dosing of CG-806 in Patients with Acute Myeloid Leukemia Benzinga

07:00AM EDT Aptose Initiates Dosing of CG-806 in Patients with Acute Myeloid GlobeNewswire Inc

Sep 15, 2020

07:30AM EDT Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and the Aptose management team will participate at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit: GlobeNewswire Inc

Sep 9, 2020

07:30AM EDT Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and the Aptose management team will participate at the upcoming conferences in September 2020: GlobeNewswire Inc

Aug 6, 2020

07:30AM EDT Aptose Biosciences to Present at Canaccord Genuity 40th Annual GlobeNewswire Inc

Aug 4, 2020

04:25PM EDT Aptose Biosciences Q2 EPS $(0.21) Misses $(0.15) Estimate Benzinga

04:01PM EDT CG-806 Phase 1 a/b Study in B Cell Malignancies Advances to Fifth (750mg) Dose Cohort GlobeNewswire Inc

05:19AM EDT Earnings Scheduled For August 4, 2020 Benzinga

Jul 21, 2020

04:01PM EDT Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the quarter ended June 30, 2020, on Tuesday, August 4, 2020, after the close of the market. GlobeNewswire Inc

Jul 17, 2020

05:08AM EDT 64 Biggest Movers From Yesterday Benzinga

Jul 15, 2020

10:49PM EDT Aptose Announces Pricing of Public Offering of Common Shares GlobeNewswire Inc

04:02PM EDT Aptose Announces A Common Stock Offering; No Size Disclosed Benzinga

04:01PM EDT Aptose Announces Proposed Public Offering of Common Shares GlobeNewswire Inc

Share